Search

Vir Biotechnology Inc

Închisă

SectorSănătate

10.65 7.47

Rezumat

Modificarea prețului

24h

Curent

Minim

9.92

Maxim

11.25

Indicatori cheie

By Trading Economics

Venit

80M

-46M

Vânzări

239M

239M

EPS

0.47

Marjă de profit

-19.09

Angajați

367

EBITDA

201M

78M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+114.83% upside

Dividende

By Acuity

Următoarele câștiguri

4 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

176M

1.7B

Deschiderea anterioară

3.18

Închiderea anterioară

10.65

Sentimentul știrilor

By Acuity

50%

50%

167 / 340 Clasament în Healthcare

Vir Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 aug. 2026, 20:09 UTC

Social Media

Vir Biotechnology is gaining as social media discussions highlight its $1 billion cash position and potential catalysts, despite earlier session pullbacks.

24 aug. 2026, 21:01 UTC

Vir Biotechnology Inc. shares are trading higher in after-market hours, continuing a recent upward trend amid a rebound in the bond market and lower Treasury yields.

21 aug. 2026, 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shows upward momentum, reflecting significant gains since Thursday's close, amid positive trends in the healthcare sector and broader biotechnology market.

20 aug. 2026, 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shares are trading lower amid a significant decline in the biotechnology sector, influenced by broader market trends and ETF performance.

19 aug. 2026, 23:06 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher in after-market trading, continuing a positive trend and maintaining a position above their 20-day moving average.

18 aug. 2026, 19:56 UTC

Vir Biotechnology Inc shares are higher today, reflecting positive market sentiment, despite a pullback from earlier session gains. The stock remains above its 20-day moving average.

17 aug. 2026, 21:02 UTC

Vir Biotechnology Inc is trading higher in after-market hours, maintaining positive momentum after eight consecutive sessions of gains and exceeding its 20-day moving average.

11 aug. 2026, 19:36 UTC

Vir Biotechnology Inc. shares are trading roughly flat amid geopolitical tensions and anticipation of U.S. inflation reports that could influence Federal Reserve policy.

10 aug. 2026, 23:56 UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

7 aug. 2026, 19:36 UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

6 aug. 2026, 23:21 UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

5 aug. 2026, 23:41 UTC

News
Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

3 aug. 2026, 19:46 UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

30 iul. 2026, 19:58 UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

29 iul. 2026, 19:27 UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

28 iul. 2026, 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

27 iul. 2026, 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

25 iul. 2026, 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

24 iul. 2026, 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

21 iul. 2026, 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20 iul. 2026, 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Comparație

Modificare preț

Vir Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

114.83% sus

Prognoză pe 12 luni

Medie 21.29 USD  114.83%

Maxim 30 USD

Minim 15 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVir Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

8

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

167 / 340 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
help-icon Live chat